Cadrenal Therapeutics (NASDAQ:CVKD) CFO Matthew Szot Sells 9,933 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CFO Matthew Szot sold 9,933 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $6.97, for a total value of $69,233.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cadrenal Therapeutics Price Performance

CVKD stock traded up $0.16 during trading on Wednesday, hitting $6.78. 18,553 shares of the company traded hands, compared to its average volume of 35,011. Cadrenal Therapeutics, Inc. has a 1 year low of $6.42 and a 1 year high of $22.90. The company has a market cap of $14.10 million, a PE ratio of -0.85 and a beta of 1.08. The stock’s 50-day simple moving average is $10.51 and its 200 day simple moving average is $11.84.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.31) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.24. Research analysts expect that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

Institutional Trading of Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Citadel Advisors LLC bought a new position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,864 shares of the company’s stock, valued at approximately $274,000. Citadel Advisors LLC owned approximately 0.96% of Cadrenal Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $32.00.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.